Sermorelin Dosage — Protocol, Timing & Clinical Evidence

Sermorelin Dosage — Protocol, Timing & Clinical Evidence

Most prescribers start sermorelin at 200–300mcg nightly. Not because that's the therapeutic dose, but because it's the lowest level at which the pituitary response can be reliably measured. The actual working dose for anti-aging and body composition outcomes sits higher: 500mcg to 1mg per injection, depending on age, baseline IGF-1 levels, and whether the patient is using it for recovery, fat loss, or age management. The gap between starting dose and maintenance dose exists because sermorelin acetate works by stimulating endogenous growth hormone release. Not replacing it directly. And the pituitary's response to GHRH (growth hormone-releasing hormone) analogs is highly individual.

Our team has guided hundreds of clients through sermorelin protocols across different clinical contexts. The difference between effective treatment and wasted money comes down to three things most guides never mention: timing the injection relative to sleep onset, measuring IGF-1 response at 4–6 weeks to confirm pituitary sensitivity, and structuring dose escalation around circadian GH pulse patterns rather than arbitrary weekly increases.

What is the correct sermorelin dosage for adults?

Sermorelin dosage for adults typically begins at 200–300mcg administered subcutaneously before bedtime, with titration to 500mcg–1mg based on IGF-1 response measured 4–6 weeks after initiation. The peptide's half-life is approximately 10–20 minutes in circulation, but the downstream GH pulse it triggers lasts 2–4 hours, making evening injection timing critical to align with natural nocturnal GH secretion. Clinical protocols published in peer-reviewed endocrinology literature show that 500mcg nightly produces measurable increases in serum IGF-1 within 3–4 weeks in roughly 70% of patients with baseline IGF-1 below the 50th percentile for age.

Sermorelin dosage isn't a one-size answer. And defining it that way misses the mechanism entirely. Sermorelin acetate is a synthetic analog of the first 29 amino acids of endogenous GHRH (the full molecule is 44 amino acids). It binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering a pulse of growth hormone release that mimics the body's natural secretion pattern. The FDA approved sermorelin acetate for diagnostic testing of GH secretion capacity. Not for therapeutic anti-aging use. But off-label prescribing for age-related GH decline is common in functional medicine and longevity-focused practices. This article covers the starting dose range used in clinical protocols, the titration schedule that aligns with pituitary receptor sensitivity, and the IGF-1 monitoring strategy that separates effective treatment from guesswork.

Starting Sermorelin Dosage: The 200–300mcg Range Explained

The sermorelin dosage starting point of 200–300mcg isn't arbitrary. It's derived from diagnostic protocols where the goal was to provoke a measurable GH response without saturating pituitary receptors. In GH stimulation tests used to diagnose GH deficiency, doses of 1mcg per kilogram of body weight (roughly 70–90mcg for a 70–90kg adult) were sufficient to trigger peak GH release within 30–60 minutes. Therapeutic protocols for age-related decline use higher doses because the objective isn't a single diagnostic pulse. It's sustained nightly augmentation of endogenous GH secretion over months.

Starting at 200mcg allows the prescriber to assess pituitary responsiveness before committing to higher doses. Patients with preserved GHRH receptor density may see IGF-1 increases at this level, while those with significant age-related decline or prior exogenous GH use (which downregulates receptors) often require 500mcg or more to produce the same downstream effect. The body's feedback loop is intact with sermorelin. Unlike exogenous recombinant GH. So higher doses don't suppress natural pulsatile secretion the way direct hormone replacement does. Titration is based on lab-confirmed IGF-1 response at 4–6 weeks, not subjective symptoms or arbitrary time intervals.

Therapeutic Sermorelin Dosage: The 500mcg–1mg Maintenance Range

Most patients who respond to sermorelin acetate settle into a maintenance dose between 500mcg and 1mg per injection, administered 5–7 nights per week. Published case series in anti-aging medicine journals report this range as the threshold where patients consistently show IGF-1 increases of 20–40% from baseline. Enough to produce measurable changes in lean mass, sleep architecture, and recovery markers without approaching supraphysiologic levels. The sermorelin dosage ceiling exists because doses above 1mg don't produce proportionally greater GH release. The pituitary's capacity to secrete GH in response to GHRH stimulation plateaus, and further dose escalation just increases cost without clinical benefit.

Timing matters as much as dose. Sermorelin must be injected 30–60 minutes before sleep onset to align with the circadian peak of natural GH secretion, which occurs 60–90 minutes after falling asleep during slow-wave sleep. Injecting sermorelin in the morning or mid-afternoon produces a GH pulse, but it's out of sync with the body's natural rhythm and yields lower IGF-1 conversion because hepatic GH receptors are less sensitive outside the nocturnal window. Patients who inject sermorelin at inconsistent times or during daylight hours often report minimal benefit despite using clinically appropriate doses. The peptide worked, but the timing sabotaged the downstream effect.

Adjusting Sermorelin Dosage Based on IGF-1 Response

IGF-1 (insulin-like growth factor 1) is the primary biomarker used to assess sermorelin efficacy because it reflects sustained GH activity over days to weeks, whereas serum GH itself has a half-life of 20–30 minutes and varies wildly throughout the day. Baseline IGF-1 should be measured before starting sermorelin, then rechecked 4–6 weeks after initiation at a stable dose. The target isn't supraphysiologic IGF-1. It's restoration to the upper-middle range for the patient's age. For a 45-year-old male, that's roughly 180–250ng/mL; for a 60-year-old, it's 120–180ng/mL. Exceeding age-adjusted reference ranges increases theoretical cancer promotion risk without additional metabolic benefit.

If IGF-1 remains flat or increases by less than 15% after 6 weeks at 300mcg, the sermorelin dosage should be increased to 500mcg. If IGF-1 response is still inadequate at 500mcg after another 4–6 weeks, escalation to 750mcg–1mg is appropriate. Non-responders. Patients who show no IGF-1 elevation despite 1mg nightly for 8+ weeks. Likely have pituitary exhaustion from prior exogenous GH use, genetic GHRH receptor polymorphisms, or advanced age-related somatotroph depletion. At that point, sermorelin is ineffective and alternatives like tesamorelin (a longer-acting GHRH analog) or direct GH replacement must be considered.

Sermorelin Dosage: Clinical Protocols Comparison

Key Takeaways

• Sermorelin dosage for adults typically starts at 200–300mcg nightly and titrates to 500mcg–1mg based on IGF-1 response measured at 4–6 weeks.
• The peptide's mechanism is GH pulse stimulation, not hormone replacement. Pituitary responsiveness determines effective dose, not body weight or age alone.
• Injection timing must align with sleep onset (30–60 minutes before bed) to synchronize with natural nocturnal GH secretion during slow-wave sleep.
• IGF-1 monitoring at baseline and 4–6 week intervals is the only reliable way to confirm sermorelin efficacy and avoid underdosing or overdosing.
• Doses above 1mg per injection rarely produce additional GH release due to pituitary saturation. Escalating beyond this threshold increases cost without clinical benefit.
• Non-responders after 8+ weeks at 1mg nightly likely have pituitary exhaustion or receptor polymorphisms and require alternative therapies.

What If: Sermorelin Dosage Scenarios

What If I Don't See Results After 6 Weeks at 300mcg?

Increase the sermorelin dosage to 500mcg and recheck IGF-1 at the 10–12 week mark. Absence of response at starting dose doesn't mean the peptide won't work. It means your pituitary requires higher GHRH receptor stimulation to produce a measurable GH pulse. Age-related decline in somatotroph density and receptor sensitivity is progressive, so older patients (55+) often need higher doses than younger patients to achieve equivalent IGF-1 increases. If IGF-1 remains flat at 500mcg after 6 additional weeks, escalate to 750mcg–1mg before concluding non-response.

What If I Miss Several Doses in a Row?

Resume at your current maintenance dose. Do not double-dose to compensate for missed injections. Sermorelin's effect is cumulative over weeks through sustained IGF-1 elevation, not dependent on daily dosing without interruption. Missing 2–3 doses won't erase prior progress, but consistent gaps (missing 3+ nights per week) will prevent stable IGF-1 levels and diminish clinical outcomes. If adherence is difficult, consider reducing frequency to 5 nights per week at a slightly higher per-injection dose rather than attempting 7-night protocols you can't maintain.

What If My IGF-1 Goes Too High on 1mg Nightly?

Reduce the sermorelin dosage to 500–750mcg or decrease injection frequency to 4–5 nights per week. Supraphysiologic IGF-1 (above the upper reference limit for your age) doesn't produce additional body composition or recovery benefits and theoretically increases cancer promotion risk in susceptible individuals. The goal is restoration to youthful levels, not pharmacologic excess. IGF-1 elevation above age-adjusted norms suggests you're a hyper-responder. Your pituitary retained high GHRH sensitivity despite chronological age, and lower doses are sufficient.

The Clinical Truth About Sermorelin Dosage

Here's the honest answer: sermorelin acetate works. But only if you dose it correctly, time it correctly, and measure the outcome objectively with IGF-1 testing. The patients who report 'sermorelin did nothing' almost always fall into one of three categories: they were underdosed at 200–300mcg and never escalated; they injected at random times of day instead of before sleep; or they never checked IGF-1 to confirm pituitary response and assumed subjective feelings were sufficient feedback. Sermorelin isn't a supplement you 'feel' working within days. It's a peptide that restores a hormonal axis over weeks, and the only way to know it's working is lab confirmation. Skipping IGF-1 monitoring is like taking blood pressure medication without ever checking your blood pressure.

The other misconception: higher doses always mean better results. Sermorelin dosage plateaus in efficacy around 1mg because the pituitary has a finite GH secretory capacity in response to GHRH stimulation. You can't force more GH release by doubling the peptide dose once you've saturated the receptors. Patients who chase subjective 'feelings' by escalating to 2mg or 3mg nightly are wasting money and peptide without gaining additional IGF-1 elevation. The dose-response curve is steep from 200–500mcg, then flattens dramatically beyond 750mcg. Smart titration is lab-driven, not symptom-driven.

Sermorelin acetate is one of the safest peptides in clinical use because it works through the body's natural regulatory mechanisms. The hypothalamic-pituitary-IGF axis remains intact, and negative feedback prevents supraphysiologic GH spikes. But safety doesn't mean it works at any dose or any schedule. The sermorelin dosage that produces measurable anti-aging benefits is narrow: too low and you're paying for placebo; too high and you're exceeding pituitary capacity without additional return. The prescribers who get consistent results with sermorelin are the ones who start conservatively, titrate based on IGF-1 data, and educate patients on circadian timing. That's the clinical reality.

The biggest mistake we see clients make isn't the injection technique. It's inconsistent timing. Sermorelin injected at 8pm one night, 11pm the next, and skipped the third night produces erratic GH pulses that don't translate into stable IGF-1 elevation. The peptide's pharmacokinetics are unforgiving: it's cleared within 30 minutes, so the window to align with nocturnal GH secretion is tight. Patients who treat sermorelin like a daily vitamin they take 'whenever I remember' rarely achieve the IGF-1 response that justifies continued use. Consistency in dose and timing isn't optional. It's the difference between therapeutic efficacy and expensive placebo.

If your prescriber didn't order baseline IGF-1 before starting you on sermorelin, find a different prescriber. If they started you at 200mcg and never mentioned dose escalation or follow-up labs, you're not being managed clinically. You're being sold a peptide. Effective sermorelin protocols require measurement, adjustment, and accountability. The dose that works for a 35-year-old with mild GH decline isn't the same dose that works for a 60-year-old with advanced somatopause. Personalization based on objective data is what separates real peptide therapy from wellness marketing.